<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="257">
  <stage>Registered</stage>
  <submitdate>11/07/2001</submitdate>
  <approvaldate>11/07/2001</approvaldate>
  <nctid>NCT00020111</nctid>
  <trial_identification>
    <studytitle>Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma</studytitle>
    <scientifictitle>Phase I Trial and Pharmacokinetic Study of Arsenic Trioxide in Pediatric Patients With Refractory Leukemia or Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>NCI-00-C-0070J</secondaryid>
    <secondaryid>CDR0000067717</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Leukemia</healthcondition>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - arsenic trioxide

Treatment: drugs: arsenic trioxide


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed leukemia or lymphoma refractory to standard curative
             treatment regimens

          -  Measurable or evaluable disease

          -  No meningeal leukemia or lymphoma

          -  No HIV-related lymphoma

          -  No lymphoproliferative diseases

        PATIENT CHARACTERISTICS:

        Age:

          -  2 to 21

               -  Acute promyelocytic leukemia (APL) patients (stratum I) must be age 2 to 12

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Bilirubin normal

          -  SGPT less than 2 times upper limit of normal

          -  No significant hepatic dysfunction that would preclude study therapy

        Renal:

          -  Creatinine normal (age adjusted) OR

          -  Creatinine clearance at least 60 mL/min

          -  Potassium, magnesium, and calcium at least lower limit of normal (oral or IV
             supplementation allowed)

          -  No significant renal dysfunction that would preclude study therapy

        Cardiovascular:

          -  Rate corrected QTc interval no greater than 0.48 on EKG

          -  No significant cardiac dysfunction that would preclude study therapy

          -  No cardiac disease, including dysrhythmias

        Pulmonary:

          -  No significant pulmonary dysfunction that would preclude study therapy

        Other:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No persistent grade 3 or greater sensory or motor neuropathy

          -  No prior grand mal seizures (grade 3 or greater) within the past 2 years other than
             febrile seizures (except for patients with APL at discretion of investigator)

          -  No clinically significant unrelated systemic illness that would preclude study therapy
             (e.g., serious infection)

          -  HIV negative

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF],
             sargramostim [GM-CSF], and epoetin alfa)

          -  No concurrent immunotherapy

        Chemotherapy:

          -  No prior arsenic trioxide

          -  At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) and recovered

          -  No concurrent intrathecal chemotherapy except for acute promyelocytic leukemia (APL)
             patients experiencing progressive meningeal leukemia and demonstrating benefit from
             arsenic trioxide for systemic disease

          -  No other concurrent anticancer chemotherapy

        Endocrine therapy:

          -  No concurrent steroids (except corticosteroids for retinoic acid syndrome)

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

          -  No concurrent radiotherapy

        Surgery:

          -  Not specified

        Other:

          -  At least 6 months since prior anticonvulsants

          -  At least 1 week since prior retinoid therapy

          -  No concurrent retinoids

          -  No other concurrent investigational agents</inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2000</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC,WA</recruitmentstate>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <hospital>Princess Margaret Hospital for Children - Perth</hospital>
    <postcode>3052 - Parkville</postcode>
    <postcode>6001 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Cancer Institute (NCI)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from
      dividing so they stop growing or die.

      PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide in
      treating young patients with leukemia or lymphoma.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00020111</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Frank M. Balis, MD</name>
      <address>National Cancer Institute (NCI)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>